Calydon, Inc.
Records under this name other than patents Calydon, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,692,736 | Cell-specific adenovirus vectors comprising an internal ribosome entry site Formerly held Term ended Term ended Jul 16, 2021 · USPTO record | Term ended | Term ended Jul 16, 2021 | USPTO record |
| US 6,991,935 | Target cell-specific adenoviral vectors containing E3 and methods of use thereof Formerly held Term ended Term ended Aug 7, 2020 · USPTO record | Term ended | Term ended Aug 7, 2020 | USPTO record |
| US 6,495,130 | Target cell-specific adenoviral vectors containing E3 and methods of use thereof Formerly held Term ended Ended no later than Dec 29, 2019 · USPTO record | Term ended | Ended no later than Dec 29, 2019 | USPTO record |
| US 7,575,919 | Adenovirus vectors containing cell status-specific response elements and methods of use thereof Formerly held Term ended Ended no later than Sep 9, 2019 · USPTO record | Term ended | Ended no later than Sep 9, 2019 | USPTO record |
| US 6,432,700 | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same Formerly held Term ended Ended no later than Mar 2, 2018 · USPTO record | Term ended | Ended no later than Mar 2, 2018 | USPTO record |
| US 6,916,918 | Human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof Formerly held Lapsed on the fee record Ended Jul 12, 2013 · USPTO record | Lapsed on the fee record | Ended Jul 12, 2013 | USPTO record |
| US 6,254,862 | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof Formerly held Lapsed on the fee record Ended Jul 3, 2013 · USPTO record | Lapsed on the fee record | Ended Jul 3, 2013 | USPTO record |
| US 6,911,200 | Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation Lapsed on the fee record Ended Jun 28, 2013 · USPTO record | Lapsed on the fee record | Ended Jun 28, 2013 | USPTO record |
| US 6,197,293 | Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof Formerly held Lapsed on the fee record Ended Mar 6, 2013 · USPTO record | Lapsed on the fee record | Ended Mar 6, 2013 | USPTO record |
| US 6,852,528 | Human and mouse uroplakin II gene transcriptional regulatory elements Formerly held Lapsed on the fee record Ended Feb 8, 2013 · USPTO record | Lapsed on the fee record | Ended Feb 8, 2013 | USPTO record |